Replies to post #9906 on Immune Pharmaceuticals Inc (fka IMNPQ)

[The Wings Of Man]

From today's 8-K even thou this news has not been posted as a company's PR

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers



On April 12, 2021, Adeel Ahmed-Daudpota, age 34, has been appointed as the President and Interim Chief Executive Officer of the Immune Pharmaceuticals to fill the vacancy that resulted from the company entering into chapter 7.



Mr. Ahmed-Daudpota is an investment banker, predominantly specializing in M&A, restructurings, and Special Situations. In connection with his appointment to the board of Immune Pharmaceuticals as Interim CEO, Mr Daudpota’s role Will entail providing the company’s shareholders options to continue trading and for identifying and merging with another viable pharmaceutical business.



The appointment as such carries no compensation and does not cover any expenses. This is subject to change post-merger.



The proposed merger is intended to protect existing shareholder interest and provide a private pharmaceutical company a public company and large shareholder base to raise additional capital.